Josep M Borras1, Michael Barton2, Cai Grau3, Julieta Corral4, Rob Verhoeven5, Valery Lemmens5, Liesbet van Eycken6, Kris Henau6, Maja Primic-Zakelj7, Primoz Strojan8, Maciej Trojanowski9, Agnieszka Dyzmann-Sroka9, Anna Kubiak9, Chiara Gasparotto10, Noemie Defourny10, Julian Malicki11, Peter Dunscombe12, Mary Coffey13, Yolande Lievens14. 1. University of Barcelona, Spain. Electronic address: jmborras@iconcologia.net. 2. CCORE, Ingham Institute for Applied Medical Research, UNSW, Liverpool, Australia. 3. Aarhus University Hospital, Denmark. 4. Doctoral Programme in Public Health, Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona, Spain. 5. The Netherlands Cancer registry/Netherlands Comprehensive Cancer Organisation, The Netherlands. 6. Belgian Cancer Registry, Brussels, Belgium. 7. Cancer registry, Institute of Oncology Ljubljana, Slovenia. 8. Dept. of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia. 9. Cancer Registry, Greater Poland Cancer Centre, Poznan, Poland. 10. European Society for Radiotherapy and Oncology, Belgium. 11. Electroradiology Dep. University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland. 12. University of Calgary, Canada. 13. Trinity College, Dublin, Ireland. 14. Ghent University Hospital, Belgium.
Abstract
BACKGROUND AND PURPOSE: The impact of differences in the distribution of major cancer sites and stages at diagnosis among 4 European countries on the optimal utilization proportion (OUP) of patients who should receive external beam radiotherapy was assessed within the framework of the ESTRO-HERO project. MATERIALS AND METHODS: Data from Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used. Population based stages at diagnosis from the cancer registries of Belgium, Slovenia, the Greater Poland region of Poland, and The Netherlands were used to assess the OUP for each country. A sensitivity analysis was carried out. RESULTS: The overall OUP by country varied from the lowest of 48.3% in Australia to the highest of 53.4% in Poland; among European countries the variation was limited to 3%. Cancer site specific OUPs showed differences according to the variability in stage at diagnosis across countries. The most important impact on the OUP by country was due to changes in relative frequency of tumours rather than stage at diagnosis. CONCLUSIONS: This methodology can be adapted using European data, thus facilitating the planning of resources required to cope with the demand for radiotherapy in Europe, taking into account the national variability in cancer incidence.
BACKGROUND AND PURPOSE: The impact of differences in the distribution of major cancer sites and stages at diagnosis among 4 European countries on the optimal utilization proportion (OUP) of patients who should receive external beam radiotherapy was assessed within the framework of the ESTRO-HERO project. MATERIALS AND METHODS: Data from Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used. Population based stages at diagnosis from the cancer registries of Belgium, Slovenia, the Greater Poland region of Poland, and The Netherlands were used to assess the OUP for each country. A sensitivity analysis was carried out. RESULTS: The overall OUP by country varied from the lowest of 48.3% in Australia to the highest of 53.4% in Poland; among European countries the variation was limited to 3%. Cancer site specific OUPs showed differences according to the variability in stage at diagnosis across countries. The most important impact on the OUP by country was due to changes in relative frequency of tumours rather than stage at diagnosis. CONCLUSIONS: This methodology can be adapted using European data, thus facilitating the planning of resources required to cope with the demand for radiotherapy in Europe, taking into account the national variability in cancer incidence.
Authors: A Rodríguez; M Algara; D Monge; J López-Torrecilla; F Caballero; R Morera; R Escó; H Pérez-Montero; C Ferrer; P C Lara Journal: Clin Transl Oncol Date: 2017-08-03 Impact factor: 3.405
Authors: Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito Journal: Cancer Treat Rev Date: 2017-07-18 Impact factor: 12.111
Authors: Eva Onjukka; Claes Mercke; Einar Björgvinsson; Anna Embring; Anders Berglund; Gabriella Alexandersson von Döbeln; Signe Friesland; Giovanna Gagliardi; Clara Lenneby Helleday; Helena Sjödin; Ingmar Lax Journal: Front Oncol Date: 2020-08-14 Impact factor: 6.244
Authors: Wei Liu; Alissa Liu; Jessica Chan; R Gabriel Boldt; Pablo Munoz-Schuffenegger; Alexander V Louie Journal: Transl Lung Cancer Res Date: 2019-09